Home > Publications database > Prognostic role of detailed colorectal location and tumor molecular features: analyses of 13,101 colorectal cancer patients including 2994 early-onset cases. > print

001     186779
005     20240229154904.0
024 7 _ |a 10.1007/s00535-023-01955-2
|2 doi
024 7 _ |a pmid:36648535
|2 pmid
024 7 _ |a 0944-1174
|2 ISSN
024 7 _ |a 0435-1339
|2 ISSN
024 7 _ |a 1435-5922
|2 ISSN
024 7 _ |a altmetric:141435814
|2 altmetric
037 _ _ |a DKFZ-2023-00107
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Ugai, Tomotaka
|b 0
245 _ _ |a Prognostic role of detailed colorectal location and tumor molecular features: analyses of 13,101 colorectal cancer patients including 2994 early-onset cases.
260 _ _ |a Tokyo
|c 2023
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1678806914_8939
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2023 Mar;58(3):229-245
520 _ _ |a The pathogenic effect of colorectal tumor molecular features may be influenced by several factors, including those related to microbiota, inflammation, metabolism, and epigenetics, which may change along colorectal segments. We hypothesized that the prognostic association of colon cancer location might differ by tumor molecular characteristics.Utilizing a consortium dataset of 13,101 colorectal cancer cases, including 2994 early-onset cases, we conducted survival analyses of detailed tumor location stratified by statuses of microsatellite instability (MSI), CpG island methylator phenotype (CIMP), and KRAS and BRAF oncogenic mutation.There was a statistically significant trend for better colon cancer-specific survival in relation to tumor location from the cecum to sigmoid colon (Ptrend = 0.002), excluding the rectum. The prognostic association of colon location differed by MSI status (Pinteraction = 0.001). Non-MSI-high tumors exhibited the cecum-to-sigmoid trend for better colon cancer-specific survival [Ptrend < 0.001; multivariable hazard ratio (HR) for the sigmoid colon (vs. cecum), 0.80; 95% confidence interval (CI) 0.70-0.92], whereas MSI-high tumors demonstrated a suggestive cecum-to-sigmoid trend for worse survival (Ptrend = 0.020; the corresponding HR, 2.13; 95% CI 1.15-3.92). The prognostic association of colon tumor location also differed by CIMP status (Pinteraction = 0.003) but not significantly by age, stage, or other features. Furthermore, MSI-high status was a favorable prognostic indicator in all stages.Both detailed colonic location and tumor molecular features need to be accounted for colon cancer prognostication to advance precision medicine. Our study indicates the important role of large-scale studies to robustly examine detailed colonic subsites in molecular oncology research.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Biogeography
|2 Other
650 _ 7 |a Epigenetics
|2 Other
650 _ 7 |a Mismatch repair
|2 Other
650 _ 7 |a Molecular pathological epidemiology
|2 Other
650 _ 7 |a Young-onset cancer
|2 Other
700 1 _ |a Akimoto, Naohiko
|b 1
700 1 _ |a Haruki, Koichiro
|b 2
700 1 _ |a Harrison, Tabitha A
|b 3
700 1 _ |a Cao, Yin
|b 4
700 1 _ |a Qu, Conghui
|b 5
700 1 _ |a Chan, Andrew T
|b 6
700 1 _ |a Campbell, Peter T
|b 7
700 1 _ |a Berndt, Sonja I
|b 8
700 1 _ |a Buchanan, Daniel D
|b 9
700 1 _ |a Cross, Amanda J
|b 10
700 1 _ |a Diergaarde, Brenda
|b 11
700 1 _ |a Gallinger, Steven J
|b 12
700 1 _ |a Gunter, Marc J
|b 13
700 1 _ |a Harlid, Sophia
|b 14
700 1 _ |a Hidaka, Akihisa
|b 15
700 1 _ |a Hoffmeister, Michael
|0 P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f
|b 16
|u dkfz
700 1 _ |a Brenner, Hermann
|0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
|b 17
|u dkfz
700 1 _ |a Chang-Claude, Jenny
|0 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
|b 18
|u dkfz
700 1 _ |a Hsu, Li
|b 19
700 1 _ |a Jenkins, Mark A
|b 20
700 1 _ |a Lin, Yi
|b 21
700 1 _ |a Milne, Roger L
|b 22
700 1 _ |a Moreno, Victor
|b 23
700 1 _ |a Newcomb, Polly A
|b 24
700 1 _ |a Nishihara, Reiko
|b 25
700 1 _ |a Obon-Santacana, Mireia
|b 26
700 1 _ |a Pai, Rish K
|b 27
700 1 _ |a Sakoda, Lori C
|b 28
700 1 _ |a Schoen, Robert E
|b 29
700 1 _ |a Slattery, Martha L
|b 30
700 1 _ |a Sun, Wei
|b 31
700 1 _ |a Amitay, Efrat
|0 P:(DE-He78)6e02c183f41e45a5867dec393fb4616a
|b 32
700 1 _ |a Alwers, Elizabeth
|0 P:(DE-He78)9b2a61b2abe4a64ca23b6783b7c4fe63
|b 33
|u dkfz
700 1 _ |a Thibodeau, Stephen N
|b 34
700 1 _ |a Toland, Amanda E
|b 35
700 1 _ |a Van Guelpen, Bethany
|b 36
700 1 _ |a Zaidi, Syed H
|b 37
700 1 _ |a Potter, John D
|b 38
700 1 _ |a Meyerhardt, Jeffrey A
|b 39
700 1 _ |a Giannakis, Marios
|b 40
700 1 _ |a Song, Mingyang
|b 41
700 1 _ |a Nowak, Jonathan A
|b 42
700 1 _ |a Peters, Ulrike
|b 43
700 1 _ |a Phipps, Amanda I
|b 44
700 1 _ |a Ogino, Shuji
|0 0000-0002-3909-2323
|b 45
773 _ _ |a 10.1007/s00535-023-01955-2
|0 PERI:(DE-600)1473159-9
|n 3
|p 229-245
|t Journal of gastroenterology
|v 58
|y 2023
|x 0944-1174
909 C O |p VDB
|o oai:inrepo02.dkfz.de:186779
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 17
|6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 18
|6 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 32
|6 P:(DE-He78)6e02c183f41e45a5867dec393fb4616a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 33
|6 P:(DE-He78)9b2a61b2abe4a64ca23b6783b7c4fe63
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2023
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2022-11-24
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2022-11-24
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2022-11-24
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-21
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J GASTROENTEROL : 2022
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-21
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-21
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b J GASTROENTEROL : 2022
|d 2023-10-21
920 1 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie und Alternf.
|x 0
920 1 _ |0 I:(DE-He78)C120-20160331
|k C120
|l Präventive Onkologie
|x 1
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 2
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C070-20160331
980 _ _ |a I:(DE-He78)C120-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21